Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1CNS 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Cyclophosphamide 909Carboplatin 786pembrolizumab 743Paclitaxel 742Cisplatin 708Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 336Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × olutasidenib × Clear all
NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
336 enrolled 48 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡